About Us
Overview
Overview
Lead by a team of top executives with innovation, vision and solid values
 
Our Mission
To leverage the knowledge, understanding, and expertise of the IC foundry industry to provide researchers in the scientific and medical fields with the highest-quality microarray products and services at affordable price so that they may be their most successful in their gene expression work.

Our History
Founded in 2002, Phalanx Biotech Group was created by several leaders from the highly regarded Industrial Technology Research Institute (ITRI) of Taiwan. Since its inception, Phalanx Biotech has remained committed to the principles on which it was founded: quality, consistency, innovation, and reliability of whole genome microarray products and services at affordable prices. Because of this, Phalanx Biotech continues to develop new products and services that are aimed at enabling researchers to do more and understand more in their work.
Throughout the world, Taiwan is recognized as one of the major epicenters of the IC industry, and ITRI has been a well-known player in helping shape this growing industry. For example, in 1998, the Biomedical Engineering Center (BMEC) within ITRI initiated the Biochip Program to explore the potential of microarray technology. Because of the success of this program, the team’s combined technical expertise produced key advancements in microfluids and microarray manufacturing. The team generated over 15 patents, which are licensed exclusively by Phalanx Biotech Group in order to promote growth in the mircorarray technology industry.
Visionary Leaders at the Top of Their Fields
Dr. Ding Hua Hu
Chairman, Phalanx Biotech Group

Chairman & CEO, Champion Venture Capitals

Board Director

Macronix International Co., Ltd.(Taiwan Stock Exchange Listed/2337)

Applied Vacuum Coating Technologies Co., Ltd.(Taiwan OTC Listed/8077)

Giga Solution Tech. Co., Ltd.(Taiwan Stock Exchange Listed/3559)


Dr. Sheng Wan Lee
Board Director & Chief Executive Officer, Phalanx Biotech Group

Founding and Managing general partner, PAC-LINK BioVentures

Board of Phalanx, Hi-Clearance Inc.(Taiwan Stock Exchange Listed/1788)

Top Scientists Provide Innovation Based on Leading-Edge Technology
Scientific Advisory Board
Dr. Chien-Jen Chen
Dr. Chen is the Vice Chairman of the National Science Council and the Professor of Public Health at the National Taiwan University. He has held a number of faculty positions including Affiliated Professor, Department of Epidemiology and Biostatistics, School of Public Health, Tulane University, U.S.A. and Senior Associate, Department of Epidemiology, School of Public Health, Johns Hopkins University, U.S.A.
Dr. Bertrand R. Jordan
Dr. Jordan, Senior Director of Research at the French National Center for Scientific Research (CNRS) (retired), is a longstanding member of EMBO (European Molecular Biology Oganisation) and HUGO (Human Genome Organisation). He has pioneered the use of DNA arrays for expression profiling, with more than 20 peer-reviewed articles on the topic since 1995. He is currently "Coordinator-Founder" of Marseille-Nice Genopole, a "genomics institute without walls" that is he set up in 2000, and member of the scientific boards of several companies including Ipsogen (Marseille, France) and PamGene (Hertzogenbosch, the Netherlands). He is also an advisor to the National Research Programme on Genomic Medicine in Taiwan.
Dr. Johnsee Lee
Dr. Lee has extensive experience in the biotech industry. He is the President of the Industrial Technology Research Institute (ITRI), Co-Director of the National Research Program on Pharmaceuticals and Biotechnology and the President of Bio Industry Organizations, Taiwan.
Dr. Lap-Chi Tsui
Dr. Tsui is past President of HUGO (Human Genome Organization), the Head Geneticist/Geneticist-in-Cheif of the Genetics and Genomic Biology Program at the Research Institute at the Hospital for Sick Children in Toronto Canada, and held the position of Professor/H.E. Sellers Chair in Cystic Fibrosis at the University of Toronto prior to his current appointment as the Vice Chancellor, University of Hong Kong.
Dr. Ching-Chung Wang
Dr. Wang is the Professor of Chemistry and Pharmaceutical Chemistry at the University of California San Francisco, U. S. A. He was also the Chairman of Integrated Chemotherapy Steering Committee of the World Health Organization (WHO) and the Director of the Institute of Molecular Biology, Academia Sinica Taiwan.
Global Leadership in a Global Economy
Board of Directors
Funding
Government
  • Ministry of Economic Affairs
  • National Science Council
Corporations
  • Yulong Group
  • China Steel Corporation
  • Maywufa Enterprise Group
  • Taiwan Fertilizer Corporation
 Venture Capital Companies
  • President Life Science
  • Walden Group
  • Industrial Technology Investment Corporation
  • Fubon Group
  • Mega International Commercial Bank
Scientific Collaboration Programs
At Phalanx Biotech, we know the importance of lead user research and the value of innovative ideas and solutions that stem from user participation. Our beta-testing programs give our partners the opportunity to use the most advanced technologies Phalanx has to offer. In return we hope to benefit from the valuable inputs of our lead users and make our products more useful to the research community. Scientific Collaboration Programs allows researchers throughout industry and academia to evaluate our developing products. Contact us to receive information regarding our programs.